Bijlage Zoekverantwoording

Onderzoeksvraag 1: behandeling van de oorzaak

Wat is het effect van behandeling van opvliegers en/of overmatig zweten als gevolg van antihormonale therapie voor mammacarcinoom of prostaatcarcinoom bij patiënten in de palliatieve fase? What is the effect of treatment of hot flashes and/or excessive sweating as a result of antihormonal therapy for breast cancer or prostate cancer in patients in the palliative phase?

Patients patients in the palliative phase with hot flashes and/or sweating as a result of antihormonal therapy for breast cancer or prostate cancer pharmacological treatment or acupuncture other pharmacological treatment, placebo, non-pharmacological therapy, sham acupuncture, no treatment critical: hot flashes (frequency/24 hours, severity/experienced burden), sweating

(NRS, VAS), quality of life important: quality of sleep, patient satisfaction, depression

Search strategy

On January 24, 2021 the scientific literature is searched in databases OVID Medline, Embase and Cochrane Library. An extra search was performed on February 24, 2021. The search strings are shown in this appendix.

The literature has been selected systematically based on the following predefined criteria:

- design: meta-analyses, systematic reviews, randomized controlled trials, controlled clinical trials
- language: English, Dutch, French, German
- publication dates: 1990 to search date
- the outcomes are reported

Literature was excluded when no quantitative data was presented, when the population was not focused on antihormonal therapy, or when the interventions where other than those focussed on depression.

Search results

The selection criteria were applied on the references yielded from the main search. 4021 unique hits were screened on title and abstract (Table 1). Of these, 3851 were excluded. Of the remaining 170 papers, the full-text was retrieved. Based on the full-text, all papers were excluded.

After the additional Medline search, 71 unique hits were screened on title and abstract (Table 1). Of these, 54 were excluded. Of the remaining 17 papers, the full-text was retrieved. Based on the full-text, all papers were excluded.

1

Table 1. Overall search results

| Database | Number of hits |
|---|----------------|
| OVID Medline: main search | 3093 |
| OVID PreMedline: main search | 7 |
| EMBASE.com | 1392 |
| Cochrane Database of Systematic Reviews | 22 |
| CENTRAL | 1342 |
| Total hits | 5856 |
| n excluded (language, duplicates) | 1841 |
| Total unique eligible hits | 4021 |
| OVID Medline: extra search | 71 |

Excluded studies

Table 2 provides an overview of the 187 excluded studies with reasons.

Table 2. Overview of excluded studies based on full-text evaluation of research question 1

| Reference | Reason for |
|---|--|
| | exclusion |
| Aaronson, T., et al. Cognitive behavioral therapy and physical exercise for climacteric symptoms in breast cancer patients experiencing treatment induced menopause: final results of a multicenter randomized controlled. Psycho-oncology., 2011. 20, 94-95. | Abstract |
| Advani, P., et al., A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy. Journal of Cancer Survivorship, 2017. 11(4): p. 477-485. | Wrong intervention |
| Ahimahalle, T.Z., et al., Clinical comparison of the effects of gabapentin and Megestrol acetate on hot flashes in patients with breast cancer. International Journal of Hematology-Oncology and Stem Cell Research, 2012. 6(1): p. 6-10. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Ahmadi, H. and S. Daneshmand, Androgen deprivation therapy: evidence-based management of side effects. BJU International, 2013. 111(4): p. 543-8. | Medline-based review |
| Anonymous, Treatment of estrogen deficiency symptoms in women surviving breast cancer. The Hormone Foundation, Canadian Breast Cancer Research Initiative, National Cancer Institute of Canada, Endocrine Society, and the University of Virginia Cancer Center and Woman's Place. Journal of Clinical Endocrinology & Metabolism, 1998. 83(6): p. 1993-2000. | Consensus conference |
| Antoine, C., et al., Safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systematic review. Climacteric, 2007. 10(1): p. 23-6. | No quality appraisal |
| Ashamalla, H., et al., Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy. International Journal of Radiation Oncology, Biology, Physics, 2011. 79(5): p. 1358-63. | No control group |
| Bao, T., et al., Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. Cancer, 2014. 120(3): p. 381-389. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Bardia, A., et al., Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis. Menopause, 2009. 16(3): p. 477-83. | Pooled analysis, but not based on systematic search and no quality appraisal |
| Barnes, K.A., et al., Nutrition care guidelines for men with prostate cancer undergoing androgen deprivation therapy: do we have enough evidence? Prostate Cancer & Prostatic Diseases, 2019. 22(2): p. 221-234. | Wrong intervention |
| Barton, D.L., et al., Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. Journal of Clinical Oncology, 1998. 16(2): p. 495-500. | DRM |
| Beckmann, M.W., et al., Hormone therapy in climactere and postmenopausal woman. A consensus of the DGGG. Geburtshilfe und Frauenheilkunde, 2003. 63(3): p. 209-212. | Consensus report |
| Beer, T.M., et al., Acupuncture for hot flashes in patients with prostate cancer. Urology, 2010. 76(5): p. 1182-8. | No control group |
| Bertelli, G., et al., Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: A randomised study. Annals of Oncology, 2002. 13(6): p. 883-888. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Biglia, N., et al., Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors. European Journal of Cancer Care, 2018. 27(1). | No advanced stages (or unclear) or no |

| Reference | Reason for exclusion |
|---|---|
| | separate analysis of advanced stages |
| Biglia, N., et al., Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas, 2005. 52(1): p. 78-85. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Biglia, N., et al., Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. Climacteric, 2009. 12(4): p. 310-8. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Biglia, N., et al., Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials. Gynecological Endocrinology, 2010. 26(11): p. 804-14. | Narrative review |
| Birkhäuser, M., et al., Recommendations of the Swiss Menopause Society: Statement on postmenopausal hormone therapy after WHI and HERS. Journal fur Menopause, 2003. 10(1): p. 7-10. | Narrative review |
| Boekhout, A.H., et al., Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: A randomized, double-blind, placebocontrolled trial. Journal of Clinical Oncology, 2011. 29(29): p. 3862-3868. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Bordeleau, L., et al., Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. Journal of Clinical Oncology, 2010. 28(35): p. 5147-52. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Bordeleau, L., et al., Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clinical Therapeutics, 2007. 29(2): p. 230-41. | No quality appraisal |
| Boyack, M., S. Lookinland, and S. Chasson, Efficacy of raloxifene for treatment of menopause: a systematic review. Journal of the American Academy of Nurse Practitioners, 2002. 14(4): p. 150-65. | Medline-search only |
| Brown, J.N. and B.R. Wright, Use of gabapentin in patients experiencing hot flashes. Pharmacotherapy, 2009. 29(1): p. 74-81. | No quality appraisal |
| | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Carpenter, J.S., et al., Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist, 2007. 12(1): p. 124-35. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Carroll, D.G. and K.W. Kelley, Use of antidepressants for management of hot flashes. Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy, 2009. 29(11): p. 1357-74. | No quality appraisal |
| Carroll, D.G., K.M. Lisenby, and T.L. Carter, Critical appraisal of paroxetine for the treatment of vasomotor symptoms. International Journal of Women's Health, 2015. 7: p. 615-624. | No quality appraisal |
| Cathcart-Rake, E., et al., A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102. Supportive Care in Cancer, 2021. 29(1): p. 387-396. | No advanced stages (or unclear) or no separate analysis of advanced stages |

| Reference | Reason for exclusion |
|---|---|
| Chan, C.W.H., et al., The effects of pharmacological and non-pharmacological interventions on symptom management and quality of life among breast cancer survivors undergoing adjuvant endocrine therapy: A systematic review. International Journal of Environmental Research and Public Health, 2020. 17(8). | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Chao, L.F., et al., The efficacy of acupoint stimulation for the management of therapy-related adverse events in patients with breast cancer: A systematic review. Breast Cancer Research and Treatment, 2009. 118(2): p. 255-267. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Cheema, D., A. Coomarasamy, and T. El-Toukhy, Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review. Archives of Gynecology & Obstetrics, 2007. 276(5): p. 463-9. | Only few sentences on breast cancer |
| Cobin, R.H., N.F. Goodman, and A.R.E.S. Committee, American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause-2017 Update. Endocrine Practice, 2017. 23(7): p. 869-880. | No systematic search |
| Cramer, H., et al., Yoga and meditation for menopausal symptoms in breast cancer survivors - A randomized controlled trial. Cancer, 2015. 121(13): p. 2175-2184. | Wrong intervention |
| Crew, K.D., et al., Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients. Journal of Cancer Survivorship, 2007. 1(4): p. 283-91. | Wrong outcomes |
| De Vos, F.Y., et al., Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline. Critical Reviews in Oncology-Hematology, 2012. 84(2): p. 252-60. | Narrative review |
| Deng, G., et al., Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. Journal of Clinical Oncology, 2007. 25(35): p. 5584-90. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Desiderio, F., et al. Homeopathy in the treatment of menopausal symptoms in patients with early breast cancer. Annals of oncology. Conference: 17th national congress of medical oncology rome italy. Conference start: 20151023 conference end: 20151025. Conference publication: (var.pagings), 2015. 26, vi25. | Abstract |
| Desmarais, J.E. and K.J. Looper, Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions. Maturitas, 2010. 67(4): p. 296-308. | No quality appraisal |
| Dimitrakakis, C., et al., Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer. Climacteric, 2005. 8(4): p. 342-51. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Dodin, S., et al. Acupuncture for menopausal hot flushes. Cochrane Database of Systematic Reviews, 2013. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Duijts, S.F., et al., Cognitive behavioral therapy and physical exercise for climacteric symptoms in breast cancer patients experiencing treatment-induced menopause: design of a multicenter trial. BMC Women's Health, 2009. 9: p. 15. | Study protocol |
| Duncan, A.M., et al., Soy isoflavones exert modest hormonal effects in premenopausal women. Journal of Clinical Endocrinology & Metabolism, 1999. 84(1): p. 192-7. | Wrong population and outcomes |

| Reference | Reason for exclusion |
|--|---|
| Elkins, G., et al., Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. Journal of Clinical Oncology, 2008. 26(31): p. 5022-6. | Wrong intervention |
| Estrogen and progestogen use in postmenopausal women: 2010 position statement of the North American menopause society. Menopause, 2010. 17(2): p. 242-255. | Medline-based review |
| Farzaneh, M. The effect of oral evening primrose oil on menopausal hot flash: a randomized clinical trial. International journal of gynecological cancer., 2013. 23, 1276. | Wrong intervention |
| Fedele, L., et al., A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. European Journal of Obstetrics and Gynecology and Reproductive Biology, 2000. 88(1): p. 91-94. | Wrong population |
| Fenlon, D., et al., MENOS4 trial: a multicentre randomised controlled trial (RCT) of a breast care nurse delivered cognitive behavioural therapy (CBT) intervention to reduce the impact of hot flushes in women with breast cancer: Study Protocol. BMC Women's Health, 2018. 18(1): p. 63. | Study protocol |
| Fenlon, D.R., J.L. Corner, and J.S. Haviland, A Randomized Controlled Trial of Relaxation Training to Reduce Hot Flashes in Women with Primary Breast Cancer. Journal of Pain and Symptom Management, 2008. 35(4): p. 397-405. | Wrong intervention |
| Forbes, M., et al. Lifestyle interventions combined with acupuncture-like transcutaneous electrical nerve stimulation in managing vasomotor symptoms induced by breast cancer treatment: results of a phase 2 randomized controlled trial. Cancer research, 2015. 75. | Abstract |
| Formoso, G., et al., Short and long term effects of tibolone in postmenopausal women. Cochrane Database of Systematic Reviews, 2012(2): p. CD008536. | Updated by Formoso 2016 |
| Formoso, G., et al., Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database of Systematic Reviews, 2016. 10: p. CD008536. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Frisk, J., et al., Acupuncture improves health-related quality-of-life (HRQoL) and sleep in women with breast cancer and hot flushes. Supportive Care in Cancer, 2012. 20(4): p. 715-724. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Frisk, J., Managing hot flushes in men after prostate cancer-A systematic review. Maturitas, 2010. 65(1): p. 15-22. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Garland, S.N., et al., Comparative effectiveness of electro-acupuncture versus gabapentin for sleep disturbances in breast cancer survivors with hot flashes: a randomized trial. Menopause, 2017. 24(5): p. 517-523. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Gaudard, A.M.I.S., et al., Bioidentical hormones for women with vasomotor symptoms. Cochrane Database of Systematic Reviews, 2016. 2016(8). | Only spontaneous or surgical menopause |
| Gerber, B., et al., Complementary and alternative therapeutic approaches in patients with early breast cancer: A systematic review. Breast Cancer Research and Treatment, 2006. 95(3): p. 199-209. | No quality appraisal |
| Gerber, G.S., et al., Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology, 2000. 55(1): p. 97-101. | No advanced stages (or unclear) or no separate analysis of advanced stages |

| Reference | Reason for exclusion |
|--|---|
| Goldberg, R.M., et al., Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. Journal of Clinical Oncology, 1994. 12(1): p. 155-8. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Goodwin, J.W., et al., Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. Journal of Clinical Oncology, 2008. 26(10): p. 1650-6. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Graf, M.C. and P.A. Geller, Treating hot flashes in breast cancer survivors: a review of alternative treatments to hormone replacement therapy. Clinical Journal of Oncology Nursing, 2003. 7(6): p. 637-40. | Narrative review |
| Grazia, L., et al. Acupuncture as an Integrated intervention for the control of symptoms of climacteric syndrome in patients affected by breast cancer: the AcCliMaT projects. European journal of integrative medicine, 2012. 4, 14-15. | Abstract |
| Grazia, L., et al. Acupuncture in the management of menopausal symptoms in women diagnosed with breast cancer: an uncontrolled experimental pilot study. European journal of integrative medicine, 2012. 4, 15. | Abstract |
| Greenlee, H., D.L. Hershman, and J.S. Jacobson, Use of antioxidant supplements during breast cancer treatment: a comprehensive review. Breast Cancer Research & Treatment, 2009. 115(3): p. 437-52. | Medline-review, no quality appraisal |
| Hadji, P., Menopausal symptoms and adjuvant therapy-associated adverse events. Endocrine-Related Cancer, 2008. 15(1): p. 73-90. | Narrative review |
| Haest, K., et al., Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up. Annals of Oncology, 2012. 23(6): p. 1449-54. | No control group |
| Hall, E., B.N. Frey, and C.N. Soares, Non-hormonal treatment strategies for vasomotor symptoms: a critical review. Drugs, 2011. 71(3): p. 287-304. | Narrative review |
| Harding, C., A. Harris, and D. Chadwick, Auricular acupuncture: a novel treatment for vasomotor symptoms associated with luteinizing-hormone releasing hormone agonist treatment for prostate cancer. BJU International, 2009. 103(2): p. 186-90. | No control group |
| Harris, B.S., et al., Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy. Menopause, 2020. 27(2): p. 243-248. | Medline-review, no quality appraisal |
| Hayes, L.P., D.G. Carroll, and K.W. Kelley, Use of gabapentin for the management of natural or surgical menopausal hot flashes. Annals of Pharmacotherapy, 2011. 45(3): p. 388-394. | Narrative review |
| Hayes, L.P., D.G. Carroll, and K.W. Kelley, Use of gabapentin for the management of natural or surgical menopausal hot flashes. Annals of Pharmacotherapy, 2011. 45(3): p. 388-94. | No quality appraisal |
| Heikkinen, J., R. Vaheri, and U. Timonen, Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses. Journal of the British Menopause Society, 2004. 10(3): p. 95-102. | Wrong population |
| Hershman, D.L., et al., Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA, 2018. 320(2): p. 167-176. | Wrong outcomes |
| Hershman, D.L., et al., Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced | Wrong outcomes |

| Reference | Reason for exclusion |
|--|---|
| Musculoskeletal Pain: SWOG S0927. Journal of Clinical Oncology, 2015. 33(17): p. 1910-7. | |
| Hervik, J. and O. Mjaland, Acupuncture for the treatment of hot flashes in breast cancer patients, a randomized, controlled trial. Breast Cancer Research & Treatment, 2009. 116(2): p. 311-6. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Hervik, J.B. and T. Stub, Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: A systematic review and meta-analysis. Breast Cancer Research and Treatment, 2016. 160(2): p. 223-236. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Heudel, P.E., et al., Does a homeopathic medicine reduce hot flushes induced by adjuvant endocrine therapy in localized breast cancer patients? A multicenter randomized placebo-controlled phase III trial. Supportive Care in Cancer, 2019. 27(5): p. 1879-1889. | Wrong intervention |
| Hickey, M., et al., Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Annals of Oncology, 2008. 19(10): p. 1669-80. | Narrative review |
| Holmberg, L., et al., HABITS (hormonal replacement therapy after breast canceris it safe?), a randomised comparison: trial stopped. Lancet, 2004. 363(9407): p. 453-5. | Comment on HABITS trial |
| Hutton, B., et al., Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a systematic review incorporating network meta-analyses. Systematic Reviews, 2015. 4: p. 114. | Review protocol |
| Irani, J., et al., Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncology, 2010. 11(2): p. 147-54. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Jacobs, J., et al., Homeopathy for menopausal symptoms in breast cancer survivors: A preliminary randomized controlled trial. Journal of Alternative and Complementary Medicine, 2005. 11(1): p. 21-27. | Wrong intervention |
| Jacobson, J.S., et al., Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. Journal of Clinical Oncology, 2001. 19(10): p. 2739-2745. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Jeong, Y.J., et al., Acupuncture for the treatment of hot flashes in patients with breast cancer receiving antiestrogen therapy: a pilot study in Korean women. Journal of Alternative & Complementary Medicine, 2013. 19(8): p. 690-6. | No control group |
| Joffe, H. Randomized study of venlafaxine with versus without zolpidem for hot flushes and associated sleep disorders in women receiving hormonal therapy for treatment or prevention of breast cancer. Physician data query (PDQ), 2004. | No full-text |
| Joffe, H., et al., Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: A randomized, double-blind, placebo-controlled trial. Menopause, 2010. 17(5): p. 908-916. | Wrong intervention |
| Johns, C., et al., Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. Breast Cancer Research & Treatment, 2016. 156(3): p. 415-426. | No advanced stages (or unclear) or no separate analysis of advanced stages |

| Reference | Reason for exclusion |
|---|---|
| Johnson, E.D. and D.G. Carroll, Venlafaxine and desvenlafaxine in the management of menopausal hot flashes. Pharmacy Practice, 2011. 9(3): p. 117-122. | No quality appraisal |
| Juliato, P.T., et al., Can polyacrylic acid treat sexual dysfunction in women with breast cancer receiving tamoxifen? Climacteric, 2017. 20(1): p. 62-66. | Wrong intervention |
| Kaari, C., et al., Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: A pilot study. Maturitas, 2006. 53(1): p. 49-58. | Wrong population |
| Kaplan, M. and S. Mahon, Hot flash management: update of the evidence for patients with cancer. Clinical Journal of Oncology Nursing, 2014. 18 Suppl: p. 59-67. | Narrative review |
| Kaplan, M., et al., Putting evidence into practice: evidence-based interventions for hot flashes resulting from cancer therapies. Clinical Journal of Oncology Nursing, 2011. 15(2): p. 149-57. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Kassab, S., et al., Homeopathic medicines for adverse effects of cancer treatments. Cochrane Database of Systematic Reviews, 2009(2). | Wrong intervention |
| Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, et al. LIBERATE Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncology 2009;10(2):135-46 | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Kenemans, P., et al., Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patientsdesign and baseline data 'LIBERATE' trial. Breast, 2007. 16 Suppl 2: p. S182-9. | Baseline data of LIBERATE trial |
| Kimmick, G.G., et al., Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast Journal, 2006. 12(2): p. 114-22. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Koch, A., et al. The role of yoga and self-esteem for menopausal symptoms and quality of life in breast cancer survivors-a mediation analysis. BMC complementary and alternative medicine, 2017. 17. | Abstract |
| Kockler, D.R. and M.W. McCarthy, Antidepressants as a treatment for hot flashes in women. American Journal of Health-System Pharmacy, 2004. 61(3): p. 287-292. | Narrative review |
| Kroiss, R., et al., The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. BJOG: An International Journal of Obstetrics & Gynaecology, 2005. 112(2): p. 228-33. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Kubista E, Planellas Gomez JVM, Dowsett M, Foidart JM, Pohlodek K, Serreyn R, et al. Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial. Clinical Cancer Research 2007;13(14):4185-90 | No endocrine therapy |
| Kubista, E., et al., Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients-Design and baseline data 'LIBERATE' trial. Breast, 2007. 16(2 SUPPL.): p. 182-189. | Abstract |
| Lammerink, E.A., et al., The management of menopausal symptoms in breast cancer survivors: case-based approach. Maturitas, 2012. 73(3): p. 265-8. | Narrative review |
| Lee, M.S., et al., Acupuncture for treating hot flashes in breast cancer patients: A systematic review. Breast Cancer Research and Treatment, 2009. 115(3): p. 497-503. | No advanced stages (or unclear) or no separate analysis of advanced stages |

| Reference | Reason for exclusion |
|--|---|
| Lesi, G., et al., Acupuncture As an Integrative Approach for the Treatment of Hot Flashes in Women With Breast Cancer: A Prospective Multicenter Randomized Controlled Trial (AcCliMaT). Journal of Clinical Oncology, 2016. 34(15): p. 1795-802. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| L'Esperance, S., et al., Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Supportive Care in Cancer, 2013. 21(5): p. 1461-74. | Medline-search only |
| Lethaby, A., et al. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database of Systematic Reviews, 2013. | Breast cancer excluded |
| Li, T., et al., Quantitative comparison of drug efficacy in treating hot flashes in patients with breast cancer. Breast Cancer Research & Treatment, 2019. 173(3): p. 511-520. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Li, XJ., et al. Clinical observation on treatment of androgen deficiency syndrome after endocrine therapy for advanced prostate cancer by "Jianpi Lishi Huayu Method". Chinese traditional and herbal drugs, 2020. 51, 5559-5565. | Chinese |
| Liljegren, A., et al., Reducing vasomotor symptoms with acupuncture in breast cancer patients treated with adjuvant tamoxifen: a randomized controlled trial. Breast Cancer Research & Treatment, 2012. 135(3): p. 791-8. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Lobo, R.A., et al., Should symptomatic menopausal women be offered hormone therapy? MedGenMed Medscape General Medicine, 2006. 8(2). | Consensus conference |
| Loibl, S., et al., Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients - A double-blind, randomized study. Annals of Oncology, 2007. 18(4): p. 689-693. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Loprinzi, C. and D. Barton Phase III randomized study of gabapentin with versus without antidepressants for the management of hot flashes in women with a history of breast cancer or a concern about taking hormonal therapy due to a fear of developing breast cancer. Physician data query (PDQ), 2004. | No full-text |
| Loprinzi, C.L., et al., A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Annals of Oncology, 2009. 20(3): p. 542-549. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Loprinzi, C.L., et al., Megestrol acetate for the prevention of hot flashes. New England Journal of Medicine, 1994. 331(6): p. 347-352. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Loprinzi, C.L., et al., Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. Journal of Clinical Oncology, 2006. 24(9): p. 1409-1414. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Loprinzi, C.L., et al., Phase III evaluation of fluoxetine for treatment of hot flashes. Journal of Clinical Oncology, 2002. 20(6): p. 1578-83. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Loprinzi, C.L., et al., Transdermal clonidine for ameliorating post-orchiectomy hot flashes. Journal of Urology, 1994. 151(3): p. 634-636. | No full-text |

| Reference | Reason for exclusion |
|---|---|
| Loprinzi, C.L., et al., Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet, 2000. 356(9247): p. 2059-63. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Mann, E., et al., Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncology, 2012. 13(3): p. 309-18. | Wrong intervention |
| Mao, J.J., et al., Electroacupuncture versus gabapentin for hot flashes among breast cancer survivors: A randomized placebo-controlled trial. Journal of Clinical Oncology, 2015. 33(31): p. 3615-3620. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Marino, J.L., H.C. McNamara, and M. Hickey, Managing menopausal symptoms after cancer: an evidence-based approach for primary care. Medical Journal of Australia, 2018. 208(3): p. 127-132. | Narrative review |
| Marjoribanks, J., et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews, 2017. | Not focused on patients with hot flushes due to breast cancer treatment |
| Marsden, J., et al., British Menopause Society consensus statement on the management of estrogen deficiency symptoms, arthralgia and menopause diagnosis in women treated for early breast cancer. Post reproductive health, 2019. 25(1): p. 21-32. | Consensus statement |
| Marshall-McKenna, R., et al., A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer. Supportive Care in Cancer, 2016. 24(4): p. 1821-9. | Wrong intervention |
| Messina, M. and C. Hughes, Efficacy of soyfoods and soybean isoflavone supplements for alleviating menopausal symptoms is positively related to initial hot flush frequency. Journal of Medicinal Food, 2003. 6(1): p. 1-11. | Narrative review |
| Milazzo, S., N. Russell, and E. Ernst, Efficacy of homeopathic therapy in cancer treatment. European Journal of Cancer, 2006. 42(3): p. 282-289. | Wrong intervention |
| Mizunuma, H., Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms. Climacteric, 2011. 14(5): p. 581-589. | Wrong population |
| Mom, C.H., et al., Hot flushes in breast cancer patients. Critical Reviews in Oncology-Hematology, 2006. 57(1): p. 63-77. | Medline-based review |
| Morrow, P.K., D.N. Mattair, and G.N. Hortobagyi, Hot flashes: a review of pathophysiology and treatment modalities. Oncologist, 2011. 16(11): p. 1658-64. | Narrative review |
| Mouridsen, H.T., Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Current Medical Research & Opinion, 2006. 22(8): p. 1609-21. | Medline-based review |
| Murthy, V. and R.S. Chamberlain, Menopausal symptoms in young survivors of breast cancer: a growing problem without an ideal solution. Cancer Control, 2012. 19(4): p. 317-29. | Medline-based review |
| Myra, H. Cognitive behaviour therapy for hot flushes and night sweats: primary and secondary analyses of three randomised controlled trials. Climacteric, 2014. 17, 43. | Abstract |
| Nedstrand, E., et al., Psychological well-being improves in women with breast cancer after treatment with applied relaxation or electro-acupuncture for | No advanced stages (or unclear) or no |

| Reference | Reason for exclusion |
|--|---|
| vasomotor symptom. Journal of Psychosomatic Obstetrics & Gynecology, 2006. 27(4): p. 193-9. | separate analysis of advanced stages |
| Nedstrand, E., et al., Vasomotor symptoms decrease in women with breast cancer randomized to treatment with applied relaxation or electro-acupuncture: a preliminary study. Climacteric, 2005. 8(3): p. 243-50. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Norris, S., et al. Clinical practice guidelines for the management of menopausal symptoms in women with a history of breast cancer. Asia-Pacific journal of clinical oncology, 2016. 12, 66 | DRM |
| Pan, Y., et al., Clinical Benefits of Acupuncture for the Reduction of Hormone Therapy–Related Side Effects in Breast Cancer Patients: A Systematic Review. Integrative Cancer Therapies, 2018. 17(3): p. 602-618. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Pandya, K.J., et al., Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet, 2005. 366(9488): p. 818-24. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Pandya, K.J., et al., Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Annals of Internal Medicine, 2000. 132(10): p. 788-93. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Peeyananjarassri, K. and R. Baber, Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: A review of randomized clinical trials. Climacteric, 2005. 8(1): p. 13-23. | No quality appraisal |
| Pirotta, M., et al., Acupuncture for menopausal vasomotor symptoms: study protocol for a randomised controlled trial. Trials [Electronic Resource], 2014. 15: p. 224. | Study protocol |
| Pitkin, J., Alternative and complementary therapies for the menopause. Menopause International, 2012. 18(1): p. 20-7. | Narrative review |
| Porzio, G., et al., Acupuncture in the treatment of menopause-related symptoms in women taking tamoxifen. Tumori, 2002. 88(2): p. 128-30. | No control group |
| | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Pruthi, S., et al., A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North central cancer treatment group N08C7. Menopause, 2012. 19(1): p. 48-53. | Wrong intervention |
| Qan'ir, Y., et al., Management of Androgen Deprivation Therapy-Associated Hot Flashes in Men With Prostate Cancer. Oncology Nursing Forum, 2019. 46(4): p. E107-E118. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Quella, S.K., et al., Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. Journal of Clinical Oncology, 2000. 18(5): p. 1068-74. | Breast cancer survivors |
| Quella, S.K., et al., Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer, 1998. 82(9): p. 1784-8. | Subset of RCT |
| Rada, G., et al., Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database of Systematic Reviews, 2010(9): p. CD004923. | No advanced stages (or unclear) or no |

| Reference | Reason for exclusion |
|--|---|
| | separate analysis of advanced stages |
| Ramaswami, R., et al., Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Research & Treatment, 2015. 152(2): p. 231-7. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Rhee, H., et al., Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU International, 2015. 115(S5): p. 3-13. | Narrative review |
| Russell, N., et al., Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial. European Journal of Endocrinology, 2018. 178(5): p. 565-576. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Santen, R.J., et al., Postmenopausal hormone therapy: an Endocrine Society scientific statement. Journal of Clinical Endocrinology & Metabolism, 2010. 95(7 Suppl 1): p. s1-s66. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Shan, D., et al., Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis. American Journal of Obstetrics & Gynecology, 2020. 222(6): p. 564-579.e12. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Sharma, P., et al., Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. Journal of Urology, 2009. 182(5): p. 2265-72. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Shi, K., et al., The maintenance effect of acupuncture on the side effects of breast cancer endocrine therapy: A protocol for systematic review and meta analysis. Medicine, 2020. 99(24): p. e20567. | Review protocol |
| Sicat, B.L. and D.K. Brokaw, Nonhormonal alternatives for the treatment of hot flashes. Pharmacotherapy: The Journal of Human Pharmacology & Drug Therapy, 2004. 24(1): p. 79-93. | Medline-based review |
| Simpson, B., Hot flash pharmacotherapy in breast cancer survivors: A literature review. Canadian Pharmaceutical Journal, 2004. 137(3): p. 36-45. | No quality appraisal |
| Sismondi, P., et al., Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients - Data from LIBERATE trial. Maturitas, 2011. 70(4): p. 365-372. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Smith, J.A., Jr., A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate. Journal of Urology, 1994. 152(1): p. 132-4. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Speroff, L., The LIBERATE tibolone trial in breast cancer survivors. Maturitas, 2009. 63(1): p. 1-3. | Editorial |
| Stearns, V., et al., Paroxetine is an effective treatment for hot flashes: Results from a prospective randomized clinical trial. Journal of Clinical Oncology, 2005. 23(28): p. 6919-6930. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Stefanopoulou, E., et al., A randomised controlled trial of a brief cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN). Psycho-Oncology, 2015. 24(9): p. 1159-66. | Wrong intervention |

| Reference | Reason for exclusion |
|--|---|
| Stovall, D.W., K. Tanner-Kurtz, and J.V. Pinkerton, Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms. Drugs, 2011. 71(13): p. 1649-57. | Narrative review |
| Stubbs, C., et al., Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women. Journal - Oklahoma State Medical Association, 2017. 110(5): p. 272-274. | Narrative review |
| Stuenkel, C.A., et al., Treatment of symptoms of the menopause: An endocrine society clinical practice guideline. 2015. p. 3975-4011. | Not really focus on right population |
| Sun, H., D. Xue, and F. Gao Effect of shugan liangxue compound for relieving hot flashes in breast cancer patients. Zhongguo zhong xi yi jie he za zhi zhongguo zhongxiyi jiehe zazhi = chinese journal of integrated traditional and western medicine, 2009. 29, 30-33. | Chinese |
| Swegle, J.M. and M.W. Kelly, Tibolone: a unique version of hormone replacement therapy. Annals of Pharmacotherapy, 2004. 38(5): p. 874-81. | Medline-based review |
| Szmulewitz, R., et al., A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer. European Urology, 2009. 56(1): p. 97-104. | Wrong outcomes |
| Tella, S.H. and J.C. Gallagher, Efficacy of desvenlafaxine succinate for menopausal hot flashes. Expert Opinion on Pharmacotherapy, 2014. 15(16): p. 2407-18. | Medline-based review |
| Thacker, H.L., Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women. Journal of Women's Health, 2011. 20(7): p. 1007-1016. | Medline-based review |
| Thompson, E.A. and D. Reilly, The homeopathic approach to the treatment of symptoms of oestrogen withdrawal in breast cancer patients. A prospective observational study. Homeopathy: the Journal of the Faculty of Homeopathy, 2003. 92(3): p. 131-4. | Wrong design, wrong intervention |
| Tice, J.A., et al., Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA, 2003. 290(2): p. 207-14. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Toulis, K.A., et al., Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clinical Therapeutics, 2009. 31(2): p. 221-35. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Tran, S., et al., Nonpharmacological therapies for the management of menopausal vasomotor symptoms in breast cancer survivors. Supportive Care in Cancer, 2020. 17: p. 17. | No quality appraisal |
| Utian, W.H., et al., Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause, 2008. 15(4): p. 584-602. | Medline-based review |
| Van Patten, C.L., et al., Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: A randomized, controlled clinical trial. Journal of Clinical Oncology, 2002. 20(6): p. 1449-1455. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Vassilopoulou-Sellin, R. and R.L. Theriault, Randomized prospective trial of estrogen-replacement therapy in women with a history of breast cancer. Journal of the National Cancer Institute. Monographs, 1994(16): p. 153-159. | DRM |
| Vieira, A.F.S., et al., Use of Guarana for hot flashes after breast cancer: Randomized, double-blind, placebo-controlled phase ii trial. Journal of Natural Remedies, 2019. 19(1): p. 1-11. | No advanced stages (or unclear) or no |

| Reference | Reason for exclusion |
|--|---|
| | separate analysis of advanced stages |
| Villaseca, P., Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice. Climacteric, 2012. 15(2): p. 115-24. | No quality appraisal |
| Vitolins, M.Z., et al., Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer. Journal of Clinical Oncology, 2013. 31(32): p. 4092-8. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| von Schoultz, E. and L.E. Rutqvist, Menopausal hormone therapy after breast cancer: The Stockholm randomized trial. Journal of the National Cancer Institute, 2005. 97(7): p. 533-535. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Walker, E.M., et al., Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. Journal of Clinical Oncology, 2010. 28(4): p. 634-40. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Wang, X.P., et al., Acupuncture for the relief of hot flashes in breast cancer patients: A systematic review and meta-analysis of randomized controlled trials and observational studies. Journal of Cancer Research & Therapeutics, 2018. 14(Supplement): p. S600-S608. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Winther, K., E. Rein, and C. Hedman, Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study. Climacteric, 2005. 8(2): p. 162-70. | Wrong population |
| Wu, MF., et al. The efficacy of sertraline for controlling menopausal symptoms in women with breast cancer. 2007. | No full-text |
| Wu, M.F., et al., The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. Breast Cancer Research & Treatment, 2009. 118(2): p. 369-75. | No advanced stages (or unclear) or no separate analysis of advanced stages |
| Yuanqing, P., et al., Acupuncture for Hormone Therapy–Related Side Effects in Breast Cancer Patients: A GRADE-Assessed Systematic Review and Updated Meta-Analysis. Integrative Cancer Therapies, 2020. 19. | No advanced stages (or unclear) or no separate analysis of advanced stages |

Search strings

MEDLINE (OVID): MAIN SEARCH

- 1 sweating/ (6851)
- 2 hyperhidrosis/ (3105)
- 3 hot flashes/ (3280)
- 4 flushing/ (1297)
- 5 climacteric/ (4886)
- 6 (flush* or flash* or sweat* or vasomotor or climacter*).mp. (94590)
- 7 exp Menopause/ (57890)
- 8 menopaus*.mp. (57031)
- 9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 (165794)
- 10 breast/ or breast diseases/ (49143)
- 11 Neoplasms/ (432386)
- 12 10 and 11 (2020)
- exp Breast Neoplasms/ (298945)
- 14 (breast\$ adj5 neoplas\$).tw. (3452)

```
15 (breast$ adj5 cancer$).tw. (262273)
```

- 16 (breast\$ adj5 carcin\$).tw. (44236)
- 17 (breast\$ adj5 tumo\$).tw. (42893)
- 18 (breast\$ adj5 metasta\$).tw. (32261)
- 19 (breast\$ adj5 malig\$).tw. (12097)
- 20 exp Carcinoma, Ductal, Breast/ (15989)
- 21 or/12-20 (362557)
- 22 exp Prostatic Neoplasms/ (130825)
- 23 (prostat\$ adj5 neoplas\$).tw. (3867)
- 24 (prostat\$ adj5 cancer\$).tw. (115278)
- 25 (prostate adj5 carcin\$).tw. (14390)
- 26 (prostate adj5 tumo\$).tw. (14101)
- 27 (prostate adj5 metasta\$).tw. (14037)
- 28 (prostate adj5 malig\$).tw. (3763)
- 29 or/22-28 (153719)
- 30 exp Androgen Antagonists/ (16264)
- 31 exp Antineoplastic Agents, Hormonal/ (175088)
- 32 exp Gonadotropin-Releasing Hormone/ag [Agonists] (3441)
- 33 hormonal.mp. (115410)
- 34 (androgen adj3 block\$).mp. (1732)
- 35 Tamoxifen/ (19247)
- 36 exp estrogen antagonists/ or exp estrogen receptor modulators/ (42970)
- 37 30 or 31 or 32 or 33 or 34 or 35 or 36 (297168)
- 38 21 or 29 (499729)
- 39 9 and 37 and 38 (6650)
- 40 randomized controlled trial.pt. (521019)
- 41 controlled clinical trial.pt. (94013)
- 42 randomized.ab. (433676)
- 43 placebo.ab. (193233)
- 44 clinical trials as topic.sh. (194395)
- 45 randomly.ab. (294337)
- 46 trial.ti. (198171)
- 47 40 or 41 or 42 or 43 or 44 or 45 or 46 (1198949)
- 48 exp animals/ not humans.sh. (4779631)
- 49 47 not 48 (1092646)
- meta-analysis.mp,pt. or review.pt. or search:.tw. (2798026)
- 51 49 or 50 (3706495)
- 52 39 and 51 (3430)
- 53 limit 52 to yr="1990 -Current" (3093)

MEDLINE (OVID): ADDITIONAL SEARCH

- 1 sweating/ (6874)
- 2 hyperhidrosis/ (3112)
- 3 hot flashes/ (3296)
- 4 flushing/ (1301)
- 5 climacteric/ (4888)
- 6 (flush* or flash* or sweat* or vasomotor or climacter*).mp. (94877)
- 7 exp Menopause/ (58092)
- 8 menopaus*.mp. (57246)
- 9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 (166362)
- 10 breast/ or breast diseases/ (49283)
- 11 Neoplasms/ (434653)
- 12 10 and 11 (2021)
- 13 exp Breast Neoplasms/ (300430)
- 14 (breast\$ adj5 neoplas\$).tw. (3458)
- 15 (breast\$ adj5 cancer\$).tw. (263895)
- 16 (breast\$ adj5 carcin\$).tw. (44339)
- 17 (breast\$ adj5 tumo\$).tw. (43120)

```
18 (breast$ adj5 metasta$).tw. (32478)
```

- 19 (breast\$ adj5 malig\$).tw. (12158)
- 20 exp Carcinoma, Ductal, Breast/ (16045)
- 21 or/12-20 (364440)
- 22 exp Prostatic Neoplasms/ (131440)
- 23 (prostat\$ adj5 neoplas\$).tw. (3874)
- 24 (prostat\$ adj5 cancer\$).tw. (115942)
- 25 (prostate adj5 carcin\$).tw. (14414)
- 26 (prostate adj5 tumo\$).tw. (14158)
- 27 (prostate adj5 metasta\$).tw. (14137)
- 28 (prostate adj5 malig\$).tw. (3782)
- 29 or/22-28 (154484)
- 30 exp Androgen Antagonists/ (16347)
- 31 exp Antineoplastic Agents, Hormonal/ (175505)
- 32 exp Gonadotropin-Releasing Hormone/ag [Agonists] (3447)
- 33 hormonal.mp. (115805)
- 34 (androgen adi3 block\$).mp. (1739)
- 35 Tamoxifen/ (19290)
- 36 exp estrogen antagonists/ or exp estrogen receptor modulators/ (43083)
- 37 30 or 31 or 32 or 33 or 34 or 35 or 36 (298034)
- 38 21 or 29 (502290)
- 39 9 and 37 and 38 (6671)
- 40 randomized controlled trial.pt. (523584)
- 41 controlled clinical trial.pt. (94062)
- 42 randomized.ab. (436847)
- 43 placebo.ab. (194082)
- 44 clinical trials as topic.sh. (194851)
- 45 randomly.ab. (296148)
- 46 trial.ti. (200017)
- 47 40 or 41 or 42 or 43 or 44 or 45 or 46 (1205234)
- 48 exp animals/ not humans.sh. (4791986)
- 49 47 not 48 (1098349)
- meta-analysis.mp,pt. or review.pt. or search:.tw. (2813283)
- 51 49 or 50 (3726195)
- 52 39 and 51 (3442)
- 53 limit 52 to yr="1990 -Current" (3105)
- 54 venlafaxin*.tw. (3617)
- 55 clonidin*.tw. (13969)
- 56 thioridazin*.tw. (2074)
- 57 gabapentin*.tw. (5686)
- 58 exp Acupuncture/ (1735)
- 59 exp Cholinergic Antagonists/ (83992)
- 60 exp Serotonin Uptake Inhibitors/ (42869)
- 61 exp "Serotonin and Noradrenaline Reuptake Inhibitors"/ (4871)
- 62 oxybutynin*.tw. (1220)
- exp Botulinum Toxins/ (16530)
- exp Aluminum Compounds/ (32919)
- 65 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 (200217)
- 66 9 and 38 and 51 and 65 (143)
- 67 limit 66 to yr="1990 -Current" (143)
- 68 67 not 53 (71)

PREMEDLINE (OVID)

- 1 sweating/(1)
- 2 hyperhidrosis/ (7)
- 3 hot flashes/ (2)
- 4 flushing/ (0)
- 5 climacteric/ (0)

```
6
        (flush* or flash* or sweat* or vasomotor or climacter*).mp. (1097)
7
        exp Menopause/ (23)
8
        menopaus*.mp. (758)
9
        1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 (1767)
10
       breast/ or breast diseases/ (33)
11
       Neoplasms/ (387)
        10 and 11 (1)
12
13
        exp Breast Neoplasms/ (278)
14
        (breast$ adj5 neoplas$).tw. (43)
15
        (breast$ adj5 cancer$).tw. (5271)
16
        (breast$ adj5 carcin$).tw. (472)
17
        (breast$ adj5 tumo$).tw. (763)
18
        (breast$ adj5 metasta$).tw. (634)
19
        (breast$ adj5 malig$).tw. (207)
20
       exp Carcinoma, Ductal, Breast/ (12)
21
       or/12-20 (5772)
        exp Prostatic Neoplasms/ (89)
22
23
        (prostat$ adj5 neoplas$).tw. (35)
24
        (prostat$ adj5 cancer$).tw. (2663)
25
        (prostate adj5 carcin$).tw. (143)
26
        (prostate adj5 tumo$).tw. (299)
27
        (prostate adj5 metasta$).tw. (388)
28
        (prostate adj5 malig$).tw. (64)
29
        or/22-28 (2808)
30
        exp Androgen Antagonists/ (12)
31
        exp Antineoplastic Agents, Hormonal/ (76)
32
        exp Gonadotropin-Releasing Hormone/ag [Agonists] (2)
33
        hormonal.mp. (1286)
        (androgen adj3 block$).mp. (34)
34
35
        Tamoxifen/ (4)
36
        exp estrogen antagonists/ or exp estrogen receptor modulators/ (16)
37
        30 or 31 or 32 or 33 or 34 or 35 or 36 (1396)
38
        21 or 29 (8279)
39
       9 and 37 and 38 (19)
40
        randomized controlled trial.pt. (409)
       controlled clinical trial.pt. (15)
41
42
       randomized.ab. (12328)
43
        placebo.ab. (3389)
44
        clinical trials as topic.sh. (88)
45
        randomly.ab. (5882)
46
       trial.ti. (5898)
47
        40 or 41 or 42 or 43 or 44 or 45 or 46 (20468)
48
        exp animals/ not humans.sh. (1903)
49
        47 not 48 (20374)
50
       meta-analysis.mp,pt. or review.pt. or search:.tw. (58607)
51
        49 or 50 (74891)
52
        39 and 51 (7)
53
       limit 52 to yr="1990 -Current" (7)
EMBASE (VIA EMBASE.COM)
#1
        'sweating'/exp (28645)
        'hyperhidrosis'/exp (9029)
#2
#3
        'hot flush'/exp (16601)
#4
        'flushing'/exp (17775)
#5
        'climacterium'/exp (9782)
        'menopausal syndrome'/exp (9030)
#6
#7
        'menopause'/exp (49428)
#8
       flush*:ti,ab OR flash*:ti,ab OR sweat*:ti,ab OR vasomotor:ti,ab OR climacter*:ti,ab (121311)
```

```
#9
       menopaus*:ti,ab (76069)
#10
       #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 (253838)
#11
       'breast'/exp OR 'breast disease'/exp (666934)
#12
       'neoplasm'/exp (5126666)
       #11 AND #12 (601736)
#13
       'breast tumor'/exp (576491)
#14
       (breast* NEAR/5 neoplas*):ti,ab (5150)
#15
#16
       (breast* NEAR/5 cancer*):ti,ab (448661)
#17
       (breast* NEAR/5 carcin*):ti,ab (65245)
#18
       (breast* NEAR/5 tumo*):ti,ab (72940)
#19
       (breast* NEAR/5 metasta*):ti,ab (60336)
       (breast* NEAR/5 malig*):ti,ab (20103)
#20
#21
       'paget nipple disease'/exp (8458)
#22
       #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 (662304)
#23
       'prostate cancer'/exp (225649)
#24
       (prostat* NEAR/5 neoplas*):ti,ab (5471)
#25
       (prostat* NEAR/5 cancer*):ti.ab (203798)
#26
       (prostat* NEAR/5 carcin*):ti,ab (27745)
#27
       (prostat* NEAR/5 tumo*):ti,ab (27152)
#28
       (prostat* NEAR/5 metasta*):ti,ab (30389)
#29
       (prostat* NEAR/5 malig*):ti,ab (7889)
#30
       #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 (275311)
#31
       #22 OR #30 (889244)
#32
       'sex hormone antagonist'/exp (182355)
#33
       'antineoplastic hormone agonists and antagonists'/exp (588544)
#34
       'gonadorelin agonist'/exp (16723)
#35
       (androgen NEAR/3 block*):ti,ab (2613)
#36
       'selective estrogen receptor modulator'/exp (7913)
#37
       #32 OR #33 OR #34 OR #35 OR #36 (660620)
#38
       #10 AND #31 AND #37 (11413)
#39
       #10 AND #31 AND #37 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta
       analysis]/lim OR randomized controlled trial]/lim) AND ([article]/lim OR [article in press]/lim OR
       [review]/lim) AND ([dutch]/lim OR [english]/lim OR [french]/lim OR [german]/lim) (1392)
COCHRANE LIBRARY (VIA WILEY)
       MeSH descriptor: [Sweating] explode all trees
#1
#2
       MeSH descriptor: [Hyperhidrosis] explode all trees
#3
       MeSH descriptor: [Hot Flashes] explode all trees
#4
       MeSH descriptor: [Flushing] explode all trees
#5
       MeSH descriptor: [Climacteric] explode all trees
#6
       MeSH descriptor: [Menopause] explode all trees
#7
       (flush* or flash* or sweat* or vasomotor or climacter* or menopaus*):ti,ab
#8
       #1 or #2 or #3 or #4 or #5 or #6 or #7
#9
       MeSH descriptor: [Breast] explode all trees
#10
       MeSH descriptor: [Breast Diseases] explode all trees
#11
       MeSH descriptor: [Neoplasms] explode all trees
#12
       #9 OR #10
#13
       #11 AND #12
#14
       MeSH descriptor: [Breast Neoplasms] explode all trees
#15
       MeSH descriptor: [Carcinoma, Ductal, Breast] explode all trees
#16
       MeSH descriptor: [Prostatic Neoplasms] explode all trees
#17
       ((breast* or prostat*) NEAR/5 (neoplas* or cancer* or carcin* or tumo* or metasta* or
malig*)):ti,ab
       #13 OR #14 OR #15 OR #16 OR #17
#18
#19
       MeSH descriptor: [Androgen Antagonists] explode all trees
       MeSH descriptor: [Antineoplastic Agents, Hormonal] explode all trees
#20
#21
       MeSH descriptor: [Gonadotropin-Releasing Hormone] explode all trees and with qualifier(s):
[agonists - AG]
```

- #22 MeSH descriptor: [Estrogen Antagonists] explode all trees
- #23 MeSH descriptor: [Estrogen Receptor Modulators] explode all trees
- #24 MeSH descriptor: [Tamoxifen] explode all trees
- #25 hormonal:ti,ab
- #26 (androgen NEAR/3 block*):ti,ab
- #27 #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26
- #28 #8 AND #18 AND #27

Onderzoeksvraag 2: medicamenteuze behandeling

Wat is het effect van medicamenteuze behandeling op overmatig zweten bij patiënten in de palliatieve fase?

What is the effect of pharmacological treatment on excessive sweating in patients in the palliative phase?

Patients patients in the palliative phase with excessive sweating

Intervention pharmacological treatment

Comparator other pharmacological treatment, placebo, no treatment

Outcome critical: sweating (NRS, VAS), quality of life

Search strategy

On February 4, 2021 the scientific literature is searched in databases OVID Medline, Embase and Cochrane Library. The search strings are shown in this appendix.

The literature has been selected systematically based on the following predefined criteria:

- design: meta-analyses, systematic reviews, randomized controlled trials, controlled clinical trials, observational comparative studies
- language: English, Dutch, French, German
- publication dates: from inception to search date
- the outcomes are reported

Literature was excluded when no quantitative data was presented, when the study population was not focused on sweating or the palliative phase, or when the interventions did not include the listed pharmacological interventions.

Search results

The selection criteria were applied on the references yielded from the search. 2744 unique hits were screened on title and abstract (Table 3). Of these, 2722 were excluded. Of the remaining 22 papers, the full-text was retrieved. Based on the full-text, all studies were excluded.

Table 3. Overall search results of research question 2.

| Database | Number of hits |
|---|----------------|
| OVID Medline | 1270 |
| OVID PreMedline | 17 |
| EMBASE.com | 1792 |
| Cochrane Database of Systematic Reviews | 29 |
| CENTRAL | 491 |
| Total hits | 3599 |
| n excluded (language, duplicates) | 855 |
| Total unique eligible hits | 2744 |

Excluded studies

Table 4 provides an overview of the excluded studies with reasons.

Table 4. Overview of excluded studies based on full-text evaluation of research question 2.

| Table 4. Overview of excluded studies based on full-text evaluation of research | question 2. |
|--|--|
| Reference | Reason for exclusion |
| Abbas, S.Q., Use of thioridazine in palliative care patients with troublesome sweating. Journal of Pain & Symptom Management, 2004. 27(3): p. 194-5. | Letter; no control group |
| Brem, S. and N.B. Kumar, Management of treatment-related symptoms in patients with breast cancer. Clinical Journal of Oncology Nursing, 2011. 15(1): p. 63-71. | Narrative review |
| Casey, C., L.M. Chen, and M.W. Rabow, Symptom management in gynecologic malignancies. Expert Review of Anticancer Therapy, 2011. 11(7): p. 1079-1091. | Narrative review |
| Catterall, R.A., Problems of sweating and transdermal fentanyl. Palliative Medicine, 1997. 11(2): p. 169-70. | Letter |
| Chan, C.W.H., et al., The effects of pharmacological and non-pharmacological interventions on symptom management and quality of life among breast cancer survivors undergoing adjuvant endocrine therapy: A systematic review. International Journal of Environmental Research and Public Health, 2020. 17(8). | Wrong populaton; breast cancer survivors |
| Chiu, S.C., et al., The therapeutic effect of modified Yu Ping Feng San on idiopathic sweating in end-stage cancer patients during hospice care. Phytotherapy Research, 2009. 23(3): p. 363-6. | No control group |
| Deaner, P., Thalidomide for distressing night sweats in advanced malignant disease. Palliative Medicine, 1998. 12(3): p. 208-9. | Letter; case report |
| Deaner, P.B., The use of thalidomide in the management of severe sweating in patients with advanced malignancy: trial report. Palliative Medicine, 2000. 14(5): p. 429-31. | No control group |
| Flaig, T.W. and L.M. Glode, Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opinion on Pharmacotherapy, 2008. 9(16): p. 2829-41. | Narrative review |
| Freeman, E.W. and K. Sherif, Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric, 2007. 10(3): p. 197-214. | No info on treatment |
| Hickey, M., C.M. Saunders, and B.G. Stuckey, Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet Oncology, 2005. 6(9): p. 687-95. | Narrative review |
| Kim, T.H. and J.W. Kang, Acupuncture for symptoms management in Korean breast cancer survivors: a prospective pilot study. Acupuncture in medicine: journal of the British Medical Acupuncture Society, 2019. 37(3): p. 164-174. | No control group |
| Miller, M., Patients with troublesome sweating. Journal of Palliative Care, 1997. 13(3): p. 53-4. | No full-text |
| Mold, J.W., B.J. Holtzclaw, and L. McCarthy, Night sweats: A systematic review of the literature. Journal of the American Board of Family Medicine, 2012. 25(6): p. 878-893. | No critical appraisal |
| Newshan, G. and D.W. Sherman, Palliative care: pain and symptom management in persons with HIV/AIDS. The Nursing clinics of North America, 1999. 34(1): p. 131-145. | DRM |
| Newton, S., Haematology and palliative care: blood, sweat and tears. Internal Medicine Journal, 2003. 33(12): p. 549-51. | Editorial |
| Peuckmann, V., M. Fisch, and E. Bruera, Potential novel uses of thalidomide: focus on palliative care. Drugs, 2000. 60(2): p. 273-92. | Narrative review; no reference to controlled studies |
| Sloan, J.A., et al., Methodologic lessons learned from hot flash studies. Journal of Clinical Oncology, 2001. 19(23): p. 4280-90. | No structured search |

| Reference | Reason for exclusion |
|---|--|
| Supportive, P.D.Q. and B. Palliative Care Editorial, Hot Flashes and Night Sweats (PDQ R): Health Professional Version. National Cancer Institute, 2002. | Narrative review; no reference to controlled studies |
| Towler, P., A. Molassiotis, and S.G. Brearley, What is the evidence for the use of acupuncture as an intervention for symptom management in cancer supportive and palliative care: An integrative overview of reviews. Supportive Care in Cancer, 2013. 21(10): p. 2913-2923. | Hot flushes; see other research question |
| Zaini, S., et al., The use of antidepressants for physical and psychological symptoms in cancer. Current Drug Targets, 2018. 19(12): p. 1431-1455. | Narrative review |
| Zhukovsky, D.S., Fever and sweats in the patient with advanced cancer. Hematology - Oncology Clinics of North America, 2002. 16(3): p. 579-88, viii. | Narrative review |

Search strings

MEDLINE (OVID)

- 1 Palliative Care/ (55452)
- 2 exp Terminal Care/ (52236)
- 3 Terminally III/ (6592)
- 4 palliat*.mp. (88508)
- 5 (terminal* adj6 (care or ill* or diseas*)).mp. (41450)
- 6 (terminal-stage* or terminal stage* or dying or (close adj6 death)).mp. (35854)
- 7 (end adj3 life).mp. (22339)
- 8 hospice*.mp. (16028)
- 9 ((end-stage* or end stage*) adj6 (disease* or illness* or care)).mp. (47113)
- 10 (incurable adj6 (disease* or illness*)).mp. (3899)
- 11 (advanced adj6 disease*).mp. (45579)
- 12 or/1-11 (257293)
- 13 sweating/ (6855)
- 14 hyperhidrosis/ (3105)
- 15 hot flashes/ (3283)
- 16 flushing/ (1298)
- 17 climacteric/ (4887)
- 18 (flush* or flash* or sweat* or vasomotor or climacter*).mp. (94654)
- 19 exp Menopause/ (57914)
- 20 menopaus*.mp. (57061)
- 21 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 (165893)
- 22 12 and 21 (1270)

PREMEDLINE (OVID)

- 1 Palliative Care/ (53)
- 2 exp Terminal Care/ (45)
- 3 Terminally III/ (5)
- 4 palliat*.mp. (1991)
- 5 (terminal* adj6 (care or ill* or diseas*)).mp. (318)
- 6 (terminal-stage* or terminal stage* or dying or (close adj6 death)).mp. (759)
- 7 (end adj3 life).mp. (1032)
- 8 hospice*.mp. (444)
- 9 ((end-stage* or end stage*) adj6 (disease* or illness* or care)).mp. (1140)
- 10 (incurable adj6 (disease* or illness*)).mp. (113)
- 11 (advanced adj6 disease*).mp. (987)
- 12 or/1-11 (5260)
- 13 sweating/ (4)
- 14 hyperhidrosis/ (0)
- 15 hot flashes/ (3)

- 16 flushing/ (1)
- 17 climacteric/(1)
- 18 (flush* or flash* or sweat* or vasomotor or climacter*).mp. (1069)
- 19 exp Menopause/ (24)
- 20 menopaus*.mp. (713)
- 21 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 (1710)
- 22 12 and 21 (17)

EMBASE (VIA EMBASE.COM)

- #1 'palliative therapy'/exp (116470)
- #2 'terminal care'/exp (72363)
- #3 'terminally ill patient'/exp (8781)
- #4 palliat*:ti,ab (122736)
- #5 (terminal* NEAR/6 (care OR caring OR ill*)):ti,ab (13227)
- #6 (end NEAR/3 life):ti,ab (36650)
- #7 hospice*:ti,ab (20776)
- #8 'terminal stage*':ti,ab (4442)
- #9 dying:ti,ab (46173)
- #10 (close NEAR/6 death):ti,ab (1374)
- #11 ((incurable OR advanced) NEAR/6 (ill* OR disease*)):ti,ab (94963)
- #12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 (357800)
- #13 'sweating'/exp
- #14 'hyperhidrosis'/exp
- #15 'hot flush'/exp
- #16 'flushing'/exp
- #17 'climacterium'/exp
- #18 'menopausal syndrome'/exp
- #19 'menopause'/exp
- #20 flush*:ti,ab OR flash*:ti,ab OR sweat*:ti,ab OR vasomotor:ti,ab OR climacter*:ti,ab (121358)
- #21 menopaus*:ti,ab
- #22 #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 (253977)
- #23 #12 AND #22 (2862)
- #24 #12 AND #22 AND ([article]/lim OR [article in press]/lim OR [review]/lim) AND ([dutch]/lim OR [english]/lim OR [french]/lim OR [german]/lim) (1792)

COCHRANE LIBRARY (VIA WILEY)

- #1 MeSH descriptor: [D010166] explode all trees
- #2 MeSH descriptor: [Terminal Care] explode all trees
- #3 MeSH descriptor: [Terminally III] explode all trees
- #4 pallia*:ti,ab
- #5 (terminal* NEAR/6 (care or caring or ill*)):ti,ab
- #6 (terminal-stage* or terminal stage* or dying or (close NEAR/6 death)):ti,ab
- #7 (end NEAR/3 life):ti,ab
- #8 hospice*:ti,ab
- #9 ((end-stage* or end stage*) NEAR/6 (disease* or ill* or care or caring)):ti,ab
- #10 ((incurable or advanced) NEAR/6 (ill* or disease*))
- #11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
- #12 MeSH descriptor: [Sweating] explode all trees
- #13 MeSH descriptor: [D006945] explode all trees
- #14 MeSH descriptor: [Hot Flashes] explode all trees
- #15 MeSH descriptor: [Flushing] explode all trees
- #16 MeSH descriptor: [Climacteric] explode all trees
- #17 MeSH descriptor: [D008593] explode all trees
- #18 (flush* or flash* or sweat* or vasomotor or climacter* or menopaus*):ti,ab
- #19 #12 or #13 or #14 or #15 or #16 or #17 or #18
- #20 #11 AND #19